Research Paper DCTN2 inhibited cellular senescence through targeting TRIM21 mediated MST2 ubiquitination and activation in hepatocellular carcinoma Yanbo Wang, Yaomei He, Qin Yu, Ningrui Wang, Qiaoling Ruan, Haiyan Wang, Hanqing Zhao, Yonglin Zhang, Yang Ke, Caie Tang, Liqi Lang, Yuxia Tang, Lixia Liu, Hao Zhang, Shan Yan, Aimin Wang, Qiushuo Shen, Ceshi Chen Theranostics 2026; 16(16): 9165-9184. Full text PDF

Research Paper Draft Genome Sequence of Multidrug-Resistant Acinetobacter baumannii smu isolated from a Bloodstream Infection in Sikkim, India Rekha Sharma, Rohit Das, Yezey Rikzing Bhutia, Neha Pradhan, Anil Bhattarai J. Genomics 2026; 14: 18-29. Full text PDF PubMed PMC

Research Paper Distinct Internalization, Acoustic Behavior and Stress Responses to Nanobubbles in Pancreatic Cancer Cells Sila Appak-Baskoy, Muhammad Saad Khan, Dhruvi Patel, Monika Lodyga, Agata A. Exner, Michael C. Kolios, Imogen R. Coe Nanotheranostics 2026; 10: 210-223. Full text PDF

Research Paper Association between FNDC5 Deficiency and Compromised Mitochondrial Integrity and Biogenesis in Kidney Disease Chien-Wei Huang, Chia-Jung Li, Junne-Ming Sung, Yau-Sheng Tsai, Jin-Shuen Chen Int. J. Med. Sci. 2026; 23(10): 3281-3295. Full text PDF

Review Protein Post-Translational Modifications in the Regulation of Ferroptosis: New Opportunities and Challenges for Cancer Immunotherapy Xin Xie, Lizhou Song, Zhaoyu Li, Jiahao Hu, Zhiheng Lin, Yadong Guo, Haoling Zhang, Wangzheqi Zhang, Zui Zou Int. J. Biol. Sci. 2026; 22(14): 7963-8007. Full text PDF

Research Paper Bevacizumab or Aflibercept in Combination with Second-Line FOLFIRI after Progression on FOLFOX Plus Bevacizumab in Metastatic Colorectal Cancer: A Comparative Study Okan Aydin, Sermin Dinc Sonusen, Asli Buyukkuscu, Seyyit Bayram Sahin, Serhat Kalkan, Ahmet Emin Ozturk, Mert Erciyestepe, Fatih Atalah, Zehra Sucuoglu Isleyen, Emir Celik, Kayhan Erturk, Muhammed Mustafa Atci J. Cancer 2026; 17(10): 1733-1743. Full text PDF

©2026 Ivyspring International Publisher. All rights reserved.
Open access content is subject to applicable licences. By accessing or using this platform, you agree to our Terms of Use.